Podcast: Amylyx Pharmaceuticals
a neuro biotech founded in the dorm room of two scrappy Brown undergrads
Unlike tech, in biotech we don't typically hear stories of multi-billion dollar companies getting started in garages or dorm rooms. Amylyx Pharmaceuticals, a neuro biotech founded in the dorm room of two scrappy Brown undergrads, is the exception.
In our podcast The World in a Grain of Sand, we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. This week, KdT Partners Mack and Rima dig into Amylyx Pharmaceuticals and discuss:
the mechanism of action of Amylyx’s lead disease-modifying asset, and competitive positioning relative to other treatments for neurodegeneration such as aducanumab
Amylyx’s capital efficiency, and reaching PhII trials without a single institutional investor
Amylyx’s unique engagement of ALS patients from the earliest days of the company, helping ensure a strong commercial launch of their ALS therapy
and more
Spotify and Apple podcast links:
For more writing and podcasts from KdT, please subscribe!
 | A guest post by
|